Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 4/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662476 | 0.94 | PTGES (0.42) | PTGESWDR5VCPTSHRSCN5A | |
| SCHEMBL12662375 | 0.92 | PTGES (0.46) | PTGESTSHRSCN5ASCN9AGRIA1 | |
| SCHEMBL12662404 | 0.90 | FAAH (0.40) | PTGESWDR5PRKCAPRKCQGSK3B | |
| SCHEMBL12662578 | 0.88 | VCP (0.40) | WDR5VCPTSHRGRIA1MAPK10 | |
| SCHEMBL12662396 | 0.88 | PTGES (0.45) | PTGESTSHRSCN5ASCN9AGRIA1 | |
| SCHEMBL12662049 | 0.87 | PRKCA (0.45) | PTGESSCN5ASCN9AGRIA1MAPK10 | |
| SCHEMBL12662553 | 0.87 | VCP (0.40) | WDR5VCPTSHRGRIA1MAPK10 | |
| SCHEMBL12662403 | 0.85 | PTGES (0.45) | PTGESGSK3BFLT3PIK3CAMTOR | |
| SCHEMBL12662400 | 0.85 | LMNA (0.45) | PTGESWDR5FLT3 | |
| SCHEMBL12662478 | 0.84 | FAAH (0.40) | PTGESWDR5FLT3PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PTGES 1022/4885WDR5 556/4885VCP 3010/4885 |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PTGES 1594/4885WDR5 644/4885VCP 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.